Compare Lemonade Inc (LMND) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Organon & Co. Common Stock — how do they compare? Lemonade Inc trades at $43.21 (market cap $3.39B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Lemonade Inc and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Organon & Co. Common Stock for 0 Days on average.
| LMND | OGN | |
|---|---|---|
Market Cap | $3.39B | $3.61B |
Volume | 1,877,282 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $96.57 | $13.81 |
52-Week Low | $43.86 | $5.70 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $3.25B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $44.71, down 0.97% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $257M in 2022 to $738M in 2025, though remains unprofitable with a -22.43% net margin. Analyst consensus is divided with a $67 price target, while technical indicators show oversold conditions with key support at $43.
Lemonade's path to profitability by late 2026 presents opportunity, but execution risks and persistent losses require caution. Expansion into new states and AI-driven efficiency improvements support growth, yet competitive pressures and cash flow challenges remain headwinds for investors seeking exposure to insurtech disruption.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
